{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:39:49Z","timestamp":1792669189716,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>We recently reported on the Molecular Microscope Diagnostic System (MMDx) to guide T-cell\u2013mediated rejection (TCMR) therapy. Donor-derived cell-free DNA (dd-cfDNA) could also assist in risk stratification of TCMR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In this cohort of 141 adult kidney transplant recipients, we assessed 3 groups based on histology, MMDx findings, and treatment decisions: untreated histologic TCMR with molecular quiescence (H+M\u2212Rx\u2212); treated histologic and molecular TCMR (H+M+Rx+; high-dose steroids and\/or anti-thymocyte globulin); and controls without rejection (H\u2212M\u2212Rx\u2212). We evaluated a 12-mo composite outcome comprising graft loss, patient death, recurrent rejection, or a \u226530% decline in estimated glomerular filtration rate from baseline. Serial dd-cfDNA levels were trended at biopsy and post-biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      At biopsy, median dd-cfDNA was higher in H+M+Rx+ (0.94%; interquartile range [IQR], 0.38%\u20132.30%) versus H+M\u2212Rx\u2212 (0.30%; IQR, 0.17%\u20130.40%) and H\u2212M\u2212Rx\u2212 (0.26%; IQR, 0.18%\u20130.51%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). Median MMDx TCMR scores and molecular acute kidney injury (AKI) scores were higher in H+M+Rx+ (TCMR: 0.40; AKI: 0.93) than H+M\u2212Rx\u2212 (TCMR: 0.01; AKI: 0.23) and H\u2212M\u2212Rx\u2212 (TCMR: 0.01; AKI: 0.12; both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). Over 12 mo, dd-cfDNA decreased in H+M+Rx+ with therapy and remained stably low in H+M\u2212Rx\u2212 and H\u2212M\u2212Rx\u2212. In a Cox proportional hazards model, molecular AKI (hazard ratio [HR], 3.20; 95% confidence interval [CI], 1.54-6.66;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.002), histologic chronic interstitial fibrosis\/tubular atrophy (HR, 1.39 per unit; 95% CI, 1.09-1.77;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.008), and dd-cfDNA at index biopsy (HR, 1.28; 95% CI, 1.04-1.57;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02) predicted the composite outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>dd-cfDNA correlated more closely with molecular TCMR than with histologic tubulitis and interstitial inflammation. Untreated histologic TCMR with molecular quiescence (by MMDx and dd-cfDNA) had clinical outcomes comparable to cases without rejection, and serial dd-cfDNA remained low despite lack of TCMR therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005820","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:00:56Z","timestamp":1782126056000},"page":"e2300-e2307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Complementary Roles of Tissue-based Gene Expression and Donor-derived Cell-free DNA for Therapy of Mild and Moderate T-cell\u2013mediated Rejection in Kidney Transplants"],"prefix":"10.1097","volume":"110","author":[{"given":"Dhiren","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louiza","family":"Azzouz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Moinuddin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Philogene","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Paulus","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Kamal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Sinhmar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Seelam","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"R1-20261022","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/TP.0000000000005296","article-title":"Tissue-based gene expression diagnosis of mild and moderate T-cell-mediated rejection to guide therapy in kidney transplants.","volume":"109","author":"Kumar","year":"2025","journal-title":"Transplantation"},{"key":"R2-20261022","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"R3-20261022","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1111\/ajt.15860","article-title":"Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection.","volume":"20","author":"Wiebe","year":"2020","journal-title":"Am J Transplant"},{"key":"R4-20261022","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R5-20261022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajt.16093","article-title":"Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: surveillance by 1-year protocol biopsies for kidney transplantation.","volume":"21","author":"Nakagawa","year":"2021","journal-title":"Am J Transplant"},{"key":"R6-20261022","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology.","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"R7-20261022","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients.","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R8-20261022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/TP.0000000000003838","article-title":"Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies.","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"key":"R9-20261022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.2021091191","article-title":"The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies.","volume":"33","author":"Halloran","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R10-20261022","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ajt.15752","article-title":"Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies.","volume":"20","author":"Madill-Thomsen","year":"2020","journal-title":"Am J Transplant"},{"key":"R11-20261022","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1097\/TP.0000000000004212","article-title":"Combining donor-derived cell-free DNA fraction and quantity to detect kidney transplant rejection using molecular diagnoses and histology as confirmation.","volume":"106","author":"Halloran","year":"2022","journal-title":"Transplantation"},{"key":"R12-20261022","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.15351","article-title":"Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers.","volume":"19","author":"Reeve","year":"2019","journal-title":"Am J Transplant"},{"key":"R13-20261022","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrneph.2016.85","article-title":"Molecular assessment of disease states in kidney transplant biopsy samples.","volume":"12","author":"Halloran","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R14-20261022","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"R15-20261022","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/ajt.15822","article-title":"High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.","volume":"20","author":"Stites","year":"2020","journal-title":"Am J Transplant"},{"key":"R16-20261022","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts.","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R17-20261022","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/TP.0000000000003278","article-title":"Impact of belatacept conversion on renal function, histology, and gene expression in kidney transplant patients with chronic active antibody-mediated rejection.","volume":"105","author":"Kumar","year":"2021","journal-title":"Transplantation"},{"key":"R18-20261022","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fimmu.2020.00074","article-title":"Extracellular vesicles as mediators of cellular crosstalk between immune system and kidney graft.","volume":"11","author":"Quaglia","year":"2020","journal-title":"Front Immunol"},{"key":"R19-20261022","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1681\/ASN.2015050524","article-title":"Relationship between eGFR decline and hard outcomes after kidney transplants.","volume":"27","author":"Clayton","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R20-20261022","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/TP.0000000000004284","article-title":"The molecular diagnosis might be clinically useful in discrepant kidney allograft biopsy findings: an analysis of clinical outcomes.","volume":"107","author":"Schachtner","year":"2023","journal-title":"Transplantation"},{"key":"R21-20261022","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1016\/j.ajt.2025.07.2470","article-title":"Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: a prospective, multicenter study.","volume":"25","author":"Bunnapradist","year":"2025","journal-title":"Am J Transplant"},{"key":"R22-20261022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:00:35Z","timestamp":1792666835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005820","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2025-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}